Vumon

Vumon information and resources from the National Cancer Institute

teniposide, VM-26

In combination with other approved anticancer agents for induction therapy in patients with refractory childhood acute lymphoblastic leukemia (all).

Bristol-Myers Squibb Jul 14 1992

Vumon -->